AAN 2022

Treatment with liraglutide — approved to treat type 2 diabetes and obesity — improved non-motor function and the ability to perform daily life activities in people with Parkinson’s disease, according to initial top-line data…

ND0612, an investigational formulation of carbidopa/levodopa delivered continuously via a subcutaneous pump, was generally well-tolerated for more than four years of treatment in a Phase 2 clinical trial of Parkinson’s patients,…

Treatment with oral IPX-203, Amneal Pharmaceuticals’ investigational extended-release carbidopa-levodopa (CD/LD) formulation, reduced “off” time by about 1.5 hours a dose, on average, compared to immediate-release tablets of the medication, according to data from…